Clinical trials: Infection, Community-Acquired
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT01602874
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Pfizer
Community-Acquired Bacterial Pneumonia (CABP)
Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the safety and efficacy of ceftaroline fosamil in elderly subjects with community-acquired bacterial pneumonia (CABP) receiving antibiotic therapy in the hospital.
- Trial name
- NCT01666743
- Testing
- Ceftaroline fosamil
- Sponsor
- Forest Laboratories
Community Acquired Pneumonia, Bacterial Pneumonia
Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment of subjects with CAP requiring hospitalization.
- Conditions
- Community Acquired Pneumonia, Bacterial Pneumonia, Cross Infection
- Trial name
- NCT00079885
- Testing
- tigecycline
- Volunteers
- 430 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Community-Acquired Infections, Bacterial Pneumonia
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization.
- Conditions
- Community-Acquired Infections, Bacterial Pneumonia, Cross Infection
- Trial name
- NCT00081575
- Testing
- Tigecycline, Levofloxacin
- Volunteers
- 434 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Community Acquired Pneumonia (CAP), Complicated Skin and Skin Structures Infections (cSSSI)
Study Evaluating Management of Patients With Community-Acquired Pneumonia (CAP) or Complicated Skin Infections
This study will collect real-life data from patients with community acquired pneumonia (CAP) OR complicated skin and skin structure infections (cSSSI) to assess the burden of the disease, review the treatment pathways, evaluate…
- Trial name
- REACH (NCT01293435)
- Where
- 163 sites in Belgium, France and 8 more
- Volunteers
- 4,035 people
- Sponsor
- AstraZeneca
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT00914888
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Community-Acquired Bacterial Pneumonia (CABP)
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
The purpose of this study is to determine the efficacy, safety and tolerability of JNJ-32729463 compared to moxifloxacin for the treatment of subjects requiring hospitalization for Community-Acquired Bacterial Pneumonia (CABP).
- Trial name
- NCT01198626
- Testing
- JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
- Where
- 34 sites in United States, Canada and 4 more
- Volunteers
- 32 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Community-Acquired Infections
Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects
To purpose of this study is to assess the safety and tolerability of intravenous (IV) tigecycline in hospitalized subjects of Japanese descent with community-acquired pneumonia (CAP).
- Trial name
- NCT00575094
- Testing
- tigecycline
- Where
- 9 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Community Acquired Infections
Tigecycline In-Vitro Surveillance Study In Taiwan
In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.
- Trial name
- NCT00488397
- Testing
- In-vitro testing
- Where
- China
- Volunteers
- 7,902 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Abdominal Abscess
Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections
The primary objective of this study is to compare the safety and efficacy of an experimental antibiotic to a marketed antibiotic in the treatment of Chinese subjects with complicated intra-abdominal infections. <br />
- Trial name
- NCT00136201
- Testing
- tigecycline
- Where
- 11 sites in China
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Community Acquired Pneumonia, Staphylococcal Skin Infections
First Time in Man Trial for Friulimicin B
The purpose of this study is to study the safety of single doses and multiple doses of Friulimicin B in healthy volunteers. The level of Friulimicin B will be measured in the subjects blood and urine.
- Trial name
- NCT00492271
- Testing
- Friulimicin B
- Where
- Switzerland
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MerLion Pharmaceuticals GmbH